KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Receivables (2016 - 2025)

Inovio Pharmaceuticals' Receivables history spans 16 years, with the latest figure at $978590.0 for Q3 2025.

  • For Q3 2025, Receivables fell 47.46% year-over-year to $978590.0; the TTM value through Sep 2025 reached $978590.0, down 47.46%, while the annual FY2024 figure was $1.2 million, 50.15% down from the prior year.
  • Receivables for Q3 2025 was $978590.0 at Inovio Pharmaceuticals, up from $840312.0 in the prior quarter.
  • Across five years, Receivables topped out at $19.9 million in Q4 2022 and bottomed at $840312.0 in Q2 2025.
  • The 5-year median for Receivables is $5.1 million (2023), against an average of $6.2 million.
  • The largest annual shift saw Receivables surged 704.09% in 2021 before it crashed 87.94% in 2023.
  • A 5-year view of Receivables shows it stood at $8.0 million in 2021, then surged by 148.21% to $19.9 million in 2022, then plummeted by 87.94% to $2.4 million in 2023, then crashed by 50.15% to $1.2 million in 2024, then dropped by 18.39% to $978590.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Receivables are $978590.0 (Q3 2025), $840312.0 (Q2 2025), and $1.3 million (Q1 2025).